Literature DB >> 1512303

Altered cytokine production in black patients with keloids.

R L McCauley1, V Chopra, Y Y Li, D N Herndon, M C Robson.   

Abstract

The treatment of keloids in black patients remains a medical dilemma. Previous studies have focused on primary alterations in the metabolism of fibroblasts as the key in the etiology of this condition. Yet alterations in the production of various cytokines which may alter fibroblast responses secondarily have received little attention. Twelve black patients with clinical and histological diagnosis of keloids and eight black control volunteers were studied. Peripheral blood mononuclear-cell (PBMC) fractions from both groups were assayed for production of interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), alpha-interferon (IFN-alpha), beta-interferon (IFN-beta), gamma-interferon (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and tumor necrosis factor-beta (TNF-beta). The production of IFN-alpha, IFN-gamma, and TNF-beta were markedly depressed in keloid patients compared to normal controls. However, IL-1 and IL-2 production was not significantly different between the two groups. In contradistinction, keloid patients produce greater amounts of IL-6, TNF-alpha, and IFN-beta. Altered levels of immunoregulatory cytokines may play a significant role in the net increase in collagen which characterizes keloid formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512303     DOI: 10.1007/bf00918154

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

1.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

2.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

Review 3.  Immunological mediators of wound healing and fibrosis.

Authors:  C W Turck; J G Dohlman; E J Goetzl
Journal:  J Cell Physiol Suppl       Date:  1987

4.  Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production.

Authors:  V Chopra; S K Tyring; L Johnson; J D Fine
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

5.  Modulation of human lymphocyte response by cartilage proteoglycans and glycosaminoglycans--a comparison between normal subjects and patients with rheumatoid arthritis.

Authors:  M Nozoe; M V Dennis; J H Herman
Journal:  Clin Immunol Immunopathol       Date:  1979-04

6.  Inhibition of human lung fibroblast growth by mononuclear cells.

Authors:  J A Elias; M D Rossman; R P Daniele
Journal:  Am Rev Respir Dis       Date:  1982-06

7.  Partial characterization of the macrophage factor that stimulates fibroblasts to produce collagenase and to degrade collagen.

Authors:  G Huybrechts-Godin; C Peeters-Joris; G Vaes
Journal:  Biochim Biophys Acta       Date:  1985-07-30

8.  Simultaneous production of interleukin 6, interferon-beta and colony-stimulating activity by fibroblasts after viral and bacterial infection.

Authors:  J Van Damme; M R Schaafsma; W E Fibbe; J H Falkenburg; G Opdenakker; A Billiau
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

9.  Inhibition of collagen synthesis by mononuclear cell supernates.

Authors:  S A Jimenez; W McArthur; J Rosenbloom
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

10.  Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s).

Authors:  I Gery; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Prevention and treatment of excessive dermal scarring.

Authors:  Ingrid E Roseborough; Mark A Grevious; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2004-01       Impact factor: 1.798

2.  Management of keloid and hypertrophic scars.

Authors:  A S Edriss; J Mesták
Journal:  Ann Burns Fire Disasters       Date:  2005-12-31

Review 3.  Incidence of hypertrophic scars among African Americans linked to vitamin D-3 metabolism?

Authors:  Gerald L Cooke; Anna Chien; Amy Brodsky; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

4.  Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways.

Authors:  Joan C Smith; Braden E Boone; Susan R Opalenik; Scott M Williams; Shirley B Russell
Journal:  J Invest Dermatol       Date:  2007-11-08       Impact factor: 8.551

5.  The role of Th1/Th2 cell chemokine expression in hypertrophic scar.

Authors:  Baoguo Chen; Huichao Li; Wei Xia
Journal:  Int Wound J       Date:  2019-11-05       Impact factor: 3.315

6.  Type 1 procollagen as a marker of severity of scarring after sternotomy: effects of topical corticosteroids.

Authors:  Y Riaz; H T Cook; A Wangoo; B Glenville; R J Shaw
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

Review 7.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 8.  Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment.

Authors:  Jonathan P Andrews; Jaana Marttala; Edward Macarak; Joel Rosenbloom; Jouni Uitto
Journal:  Matrix Biol       Date:  2016-02-02       Impact factor: 11.583

9.  Chemokine and chemokine receptor expression in keloid and normal fibroblasts.

Authors:  C S Nirodi; R Devalaraja; L B Nanney; S Arrindell; S Russell; J Trupin; A Richmond
Journal:  Wound Repair Regen       Date:  2000 Sep-Oct       Impact factor: 3.617

10.  Hepatoma-derived growth factor and its role in keloid pathogenesis.

Authors:  B N S Ooi; A Mukhopadhyay; J Masilamani; D V Do; C P Lim; X M Cao; I J Lim; L Mao; H N Ren; H Nakamura; T T Phan
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.